Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2024 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

regeneron pharmaceuticals inc. - REGN

REGN

Close Chg Chg %
744.50 -6.50 -0.87%

Closed Market

738.00

-6.50 (0.87%)

Volume: 1.03M

Last Updated:

Nov 22, 2024, 4:00 PM EDT

Trade Now

Company Overview: regeneron pharmaceuticals inc. - REGN

REGN Key Data

Open

$744.70

 Day Range

737.63 - 751.40

52 Week Range

735.95 - 1,211.20

 Market Cap

$81.81B

Shares Outstanding

109.89M

 Public Float

105.94M

Beta

0.14

 Rev. Per Employee

N/A

P/E Ratio

18.42

 EPS

$43.23

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

864.10K

  

REGN Performance

1 Week
 
 -1.63%
 
1 Month
 
 -20.21%
 
3 Months
 
 -37.91%
 
1 Year
 
 -6.74%
 
5 Years
 
 106.43%
 

REGN Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 30
Full Ratings ➔

About regeneron pharmaceuticals inc. - REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

REGN At a Glance

Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591-6707
Phone 1-914-847-7000 Revenue 13.12B
Industry Pharmaceuticals: Major Net Income 3.95B
Sector Health Technology 2023 Sales Growth 7.757%
Fiscal Year-end 12 / 2024 Employees 13,450
View SEC Filings

REGN Valuation

P/E Current 18.423
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 25.258
Price to Sales Ratio 7.613
Price to Book Ratio 3.699
Price to Cash Flow Ratio 21.737
Enterprise Value to EBITDA 19.23
Enterprise Value to Sales 6.992
Total Debt to Enterprise Value 0.029

REGN Efficiency

Revenue/Employee 975,256.506
Income Per Employee 293,947.955
Receivables Turnover 2.315
Total Asset Turnover 0.42

REGN Liquidity

Current Ratio 5.69
Quick Ratio 4.936
Cash Ratio 3.168

REGN Profitability

Gross Margin 82.889
Operating Margin 33.152
Pretax Margin 32.014
Net Margin 30.141
Return on Assets 12.671
Return on Equity 16.258
Return on Total Capital 13.787
Return on Invested Capital 14.632

REGN Capital Structure

Total Debt to Total Equity 10.407
Total Debt to Total Capital 9.426
Total Debt to Total Assets 8.158
Long-Term Debt to Equity 10.407
Long-Term Debt to Total Capital 9.426
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Regeneron Pharmaceuticals Inc. - REGN

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
8.50B 16.07B 12.17B 13.12B
Sales Growth
+8.06% +89.14% -24.26% +7.76%
Cost of Goods Sold (COGS) incl D&A
1.36B 2.72B 1.71B 2.24B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
235.90M 286.20M 341.40M 421.00M
Depreciation
235.90M 286.20M 303.80M 328.80M
Amortization of Intangibles
- - 37.60M 92.20M
-
COGS Growth
+36.60% +100.89% -37.39% +31.63%
Gross Income
7.14B 13.35B 10.47B 10.87B
Gross Income Growth
+3.94% +86.91% -21.58% +3.87%
Gross Profit Margin
+84.04% +83.05% +85.99% +82.89%
2020 2021 2022 2023 5-year trend
SG&A Expense
3.85B 4.45B 5.17B 6.53B
Research & Development
2.50B 2.62B 3.06B 3.99B
Other SG&A
1.35B 1.82B 2.12B 2.54B
SGA Growth
-17.51% +15.65% +16.31% +26.18%
Other Operating Expense
(280.40M) (45.60M) (89.90M) (2.10M)
Unusual Expense
(196.00M) (386.10M) 686.50M 539.30M
EBIT after Unusual Expense
3.77B 9.33B 4.70B 3.81B
Non Operating Income/Expense
94.70M 50.20M 219.10M 463.00M
Non-Operating Interest Income
- - 160.10M 495.90M
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
56.90M 57.30M 59.40M 73.00M
Interest Expense Growth
+88.41% +0.70% +3.66% +22.90%
Gross Interest Expense
56.90M 57.30M 59.40M 73.00M
Interest Capitalized
- - - -
-
Pretax Income
3.81B 9.33B 4.86B 4.20B
Pretax Income Growth
+56.86% +144.75% -47.90% -13.57%
Pretax Margin
+44.84% +58.03% +39.91% +32.01%
Income Tax
297.20M 1.25B 520.40M 245.70M
Income Tax - Current - Domestic
200.20M 1.44B 975.90M 675.60M
Income Tax - Current - Foreign
21.40M (38.40M) 290.90M 407.90M
Income Tax - Deferred - Domestic
107.00M (423.80M) (800.40M) (841.00M)
Income Tax - Deferred - Foreign
(31.40M) 276.70M 54.00M 3.20M
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
3.51B 8.08B 4.34B 3.95B
Minority Interest Expense
- - - -
-
Net Income
3.51B 8.08B 4.34B 3.95B
Net Income Growth
+66.05% +129.86% -46.28% -8.87%
Net Margin Growth
+41.35% +50.25% +35.64% +30.14%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
3.51B 8.08B 4.34B 3.95B
Preferred Dividends
- - - -
-
Net Income Available to Common
3.51B 8.08B 4.34B 3.95B
EPS (Basic)
32.6506 76.3983 40.5079 37.0534
EPS (Basic) Growth
+68.51% +133.99% -46.98% -8.53%
Basic Shares Outstanding
107.60M 105.70M 107.10M 106.70M
EPS (Diluted)
30.523 71.9724 38.2238 34.7722
EPS (Diluted) Growth
+65.32% +135.80% -46.89% -9.03%
Diluted Shares Outstanding
115.10M 112.20M 113.50M 113.70M
EBITDA
3.81B 9.23B 5.73B 4.77B
EBITDA Growth
+57.53% +142.18% -37.97% -16.72%
EBITDA Margin
+44.87% +57.45% +47.05% +36.36%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 1,090.50
Number of Ratings 30 Current Quarters Estimate 11.087
FY Report Date 12 / 2024 Current Year's Estimate 44.841
Last Quarter’s Earnings 12.46 Median PE on CY Estimate N/A
Year Ago Earnings 43.79 Next Fiscal Year Estimate 45.036
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 24 6 25 25
Mean Estimate 11.09 10.94 44.84 45.04
High Estimates 13.62 12.84 47.19 51.95
Low Estimate 8.57 8.89 42.77 39.55
Coefficient of Variance 11.46 11.90 2.43 8.24

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 18 16 17
OVERWEIGHT 2 2 3
HOLD 9 8 5
UNDERWEIGHT 1 2 1
SELL 0 0 1
MEAN Overweight Overweight Overweight

Insider Actions for Regeneron Pharmaceuticals Inc. - REGN

Date Name Shares Transaction Value
Oct 4, 2024 Arthur Frederick Ryan Director 17,679 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $1041.35 per share 18,410,026.65
Oct 4, 2024 Arthur Frederick Ryan Director 17,636 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $1047.44 per share 18,472,651.84
Oct 4, 2024 Arthur Frederick Ryan Director 17,582 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $1059.28 per share 18,624,260.96
Oct 4, 2024 Arthur Frederick Ryan Director 17,584 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $1057.38 per share 18,592,969.92
Oct 4, 2024 Arthur Frederick Ryan Director 17,586 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $1056.68 per share 18,582,774.48
Oct 4, 2024 Arthur Frederick Ryan Director 17,589 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $1054.9 per share 18,554,636.10
Oct 4, 2024 Arthur Frederick Ryan Director 17,592 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $1053.45 per share 18,532,292.40
Oct 4, 2024 Marion McCourt EVP Commercial 7,000 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Oct 4, 2024 Marion McCourt EVP Commercial 12,931 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $1054.06 per share 13,630,049.86
Oct 4, 2024 Marion McCourt EVP Commercial 13,931 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $381.4 per share 5,313,283.40
Oct 4, 2024 Arthur Frederick Ryan Director 17,609 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $1050.6 per share 18,500,015.40
Oct 4, 2024 Arthur Frederick Ryan Director 17,624 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $1048.54 per share 18,479,468.96
Oct 4, 2024 Arthur Frederick Ryan Director 17,657 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $1045.27 per share 18,456,332.39
Oct 4, 2024 Arthur Frederick Ryan Director 17,664 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $1044.62 per share 18,452,167.68
Oct 4, 2024 Arthur Frederick Ryan Director 17,648 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $1046.53 per share 18,469,161.44
Oct 4, 2024 Arthur Frederick Ryan Director 17,673 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $1043.39 per share 18,439,831.47
Oct 4, 2024 Arthur Frederick Ryan Director 17,615 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $1049.68 per share 18,490,113.20
Oct 4, 2024 Arthur Frederick Ryan Director 17,600 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $1051.51 per share 18,506,576.00
Oct 4, 2024 Arthur Frederick Ryan Director 17,678 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $1042.31 per share 18,425,956.18
Oct 4, 2024 Arthur Frederick Ryan Director 17,596 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $1052.44 per share 18,518,734.24

Regeneron Pharmaceuticals Inc. in the News